Breaking News, Collaborations & Alliances

Poseida Nominates New Development Candidate Under Its Collaboration with Roche

The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in hematologic malignancies.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Poseida Therapeutics Inc., a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, has nominated a new development candidate under its collaboration with Roche.
 
The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in hematologic malignancies, including multiple myeloma.
 
The large capacity of Poseida’s non-viral transposon-based DNA delivery system enables the insertion of genes for two full length chimeric antigen receptors (CARs) into T stem cell memory cells (TSCM).
 
“The nomination of a new development candidate builds on our collaboration with Roche and highlights the unique potential of our proprietary non-viral genetic engineering toolkit to create differentiated, TSCM-rich allogeneic CAR-T therapies targeting one or more antigens,” said Kristin Yarema, Ph.D., president and CEO of Poseida Therapeutics. “Multiple myeloma is a common and incurable blood cancer with significant room for potent, safe and accessible novel agents to expand use across lines of therapy and sites of care. With compelling preclinical data supporting the target combination of this dual CAR-T, we look forward to advancing this program towards the clinic as a part of the collaboration. We also look forward to providing updates on our CAR-T programs and earlier-stage pipeline at Poseida’s upcoming Cell Therapy R&D Day.”
 
Poseida and Roche now have three programs under their collaboration, which was established in August 2022 to develop allogeneic CAR-T therapies directed to hematologic malignancies.
 
The nomination triggered a $15 million milestone payment from Roche to Poseida.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters